Pharmacology News

The Infectious Diseases Society of America released updated guidelines on complicated intra-abdominal infections for the first time since 2010.

Bayer announced positive top-line results for the FINEARTS-HF trial of finerenone, in which the drug reduced risk for cardiovascular death and heart failure events in patients with HF with preserved or mildly reduced ejection fraction.

A generally healthy 42-year-old female presents for evaluation of anxiety, tremors, weight loss, loose stools and heart racing. Symptoms began shortly after she was let go at work about 4 months ago.

In June, the CDC began recommending doxycycline post-exposure prophylaxis — or doxy-PEP, as it is commonly known — as a prevention strategy for STIs in certain high-risk populations.

Using the American Heart Association’s new PREVENT risk calculator would mean reducing eligibility for statin and/or antihypertensive therapy by approximately 16 million U.S. adults, researchers reported in JAMA.

There are many important factors primary care providers must consider when prescribing popular anti-obesity medications, according to experts.

Despite global progress toward eliminating HIV — including a growing number of nations that have hit goals to diagnose and successfully treat patients — funding pullbacks threaten to add decades to the battle, according to a study.

Johnson & Johnson announced that it has submitted a supplemental new drug application for the approval of esketamine nasal spray as a monotherapy for adults with treatment-resistant depression.

Post-exposure prophylaxis for HIV remained significantly underutilized, especially in acute care settings, according to study results published in Open Forum Infectious Diseases.

Long-acting injectable PrEP is feasible and acceptable to both men and women, according to a study presented at the AIDS 2024 meeting in Munich.